This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Dow 30 Stock Roundup: Apple Apologizes for iPhone Issue, Disney's The Last Jedi Crosses $1B Mark
by Swarup Gupta
The Dow started the year on a strong note, gaining over three successive sessions.
Merck's Keytruda Gets Approved for Bladder Cancer in Japan
by Zacks Equity Research
Merck's (MRK) anti-PD-1 therapy, Keytruda, gains approval in Japan for previously-treated patients with bladder cancer. Keytruda can now be indicated for four types of cancer in Japan.
Seattle Genetics' Adcetris sBLA Gets FDA Priority Review
by Zacks Equity Research
Seattle Genetics' supplemental Biologics License Application for the label expansion of its lymphoma drug, Adcetris, was accepted by the FDA and granted priority review.
4 Reasons to Include Celldex (CLDX) Stock in Your Portfolio
by Zacks Equity Research
Celldex stock has been performing well for the last six months and the momentum is likely to continue in the near term.
ImmunoGen (IMGN) Soars Above 200% This Year: Here's Why
by Zacks Equity Research
ImmunoGen's (IMGN) shares shoot up in the year on rapid pipeline progress, positive study data and strategic collaborations.
Merck's Diabetes Drugs Get FDA Nod as Adjunct Therapies
by Zacks Equity Research
Merck's (MRK) three diabetes drugs get FDA approval as adjunct treatment to diet and exercise to improve glycemic control in patients with diabetes mellitus.
Dow 30 Stock Roundup: Nike Beats, Pfizer Hikes Dividend
by Swarup Gupta
The Dow traversed a choppy week even as the much vaunted tax legislation finally gained legislative approval
Why is Nektar (NKTR) Stock Up More Than 350% This Year?
by Zacks Equity Research
Nektar's (NKTR) shares soar in the year so far on a robust pipeline including several study initiations and strategic collaborations.
Roche's Perjeta Gets FDA Nod for Post Surgery Breast Cancer
by Zacks Equity Research
Roche's (RHHBY) Perjeta in combination with Herceptin and chemotherapy (the Perjeta-based regimen), gets FDA nod for adjuvant (after surgery) treatment of HER2-positive early breast cancer at high risk of recurrence
Bristol-Myers Yervoy Gets Positive CHMP Opinion for Melanoma
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) immuno-oncology drug Yervoy gets positive opinion from the CHMP of the European Medicines Agency for the treatment of pediatric patients of 12 years and older with unresectable or metastatic melanoma.
Merck's Keytruda Misses Primary End Point for Gastric Cancer
by Zacks Equity Research
Merck's (MRK) anti-PD-1 therapy Keytruda misses the primary endpoint in a phase III study, which analyzed it as a second-line treatment for patients with advanced gastric adenocarcinoma.
Bristol-Myers' Opdivo/Yervoy sBLA for RCC Accepted by FDA
by Zacks Equity Research
Bristol-Myers (BMY) supplemental Biologics License Application (sBLA) for Opdivo and Yervoy combination for the treatment of intermediate- and poor-risk patients with advanced renal cell carcinoma was accepted by the FDA.
Merck's Keytruda Gets FDA Priority Review for Rare Lymphoma
by Zacks Equity Research
Merck (MRK) informs that the FDA grants a priority review to its supplemental biologics license application looking for its marketed drug Keytruda's label expansion for a rare lymphoma indication.
4 Drug/Biotech Stocks That Could Be Buyout Targets in 2018
by Zacks Equity Research
Biotech mergers and acquisitions, which were quite lean in 2017, may pick up significantly in 2018 if the proposed tax reforms are finally approved.
Can Drug/Biotech M&A Rebound Next Year After Bleak 2017?
by Zacks Equity Research
Quite a few pharmaceutical industry mergers may be in the cards in 2018 if the proposed tax reforms are finally approved.
The Zacks Analyst Blog Highlights: Home Depot, Boeing, Merck, Allstate and Illumina
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Home Depot, Boeing, Merck, Allstate and Illumina
Top Analyst Reports for Home Depot, Boeing & Merck
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Home Depot (HD), Boeing (BA) and Merck (MRK).
Bristol-Myers' Opdivo's Lung Cancer Study Meets Early Success
by Zacks Equity Research
Bristol-Myers' (BMY) phase III study evaluating Opdivo versus docetaxel was stopped earlier than expected as it met the primary endpoint.
Glaxo Stock Down So Far This Year: Is a Reversal in Store?
by Zacks Equity Research
Glaxo's shares have declined 7.9% this year so far.
Merck Announces $10 Billion Buyback, Hikes Dividend by 2.1%
by Zacks Equity Research
Merck (MRK) rewards shareholders with a hike in quarterly dividend. Also, the company's board of directors sanctions a new stock buyback plan.
Options Traders Expect Huge Moves in Merck & Co. (MRK) Stock
by Zacks Equity Research
Investors in Merck & Co. (MRK) need to pay close attention to the stock based on moves in the options market lately.
Why Is ImmunoGen (IMGN) Stock Up More Than 150% This Year?
by Zacks Equity Research
ImmunoGen's (IMGN) shares shoot up in the year so far on rapid pipeline progress plus positive study data and strategic collaborations.
Nektar (NKTR) Stock Up More than 300% This Year: Here's Why
by Zacks Equity Research
Nektar's (NKTR) shares skyrocket in the year so far on a robust pipeline including several study initiations and strategic collaborations.
J&J & Glaxo's Juluca Approval Puts Spotlight on HIV Space (Revised)
by Zacks Equity Research
As HIV and AIDS have limited medical cure but huge medical need, we see how different companies are trying to tap into this huge market.
TESARO (TSRO) Ovarian Cancer Drug Zejula Gets Approval in EU
by Zacks Equity Research
TESARO (TSRO) received a boost with the approval of Zejula in Europe for ovarian cancer, following its approval in the United States earlier this year.